

MAR 26 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

LAW OFFICES OF JONATHAN ALAN QUINE

By:

Atty Docket No.: 407T-899210US

Client Ref: 2000-283-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**ALAN M. FOGELMAN and
MOHAMAD NAVAB**

Application No.: 09/994,227

Filed: 11/26/2001

For: **CONTROL OF A GENE
INDUCED BY OXIDIZED LIPIDS IN
HUMAN ARTERY WALL CELLS**

Examiner: unassigned

Art Unit: unassigned

**PRELIMINARY AMENDMENT TO
ACCOMPANY NOTICE OF MISSING
PARTS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This preliminary amendment accompanies the Notice to File Missing Parts of Nonprovisional Application mailed on January 25, 2002 containing instructions to comply with the requirements of 37 C.F.R. §§1.821-1.825. The following documents are enclosed herewith:

- 1) An initial Computer readable form (CRF) copy of the Sequence Listing; and
- 2) An substitute paper copy of the Sequence Listing.

Please amend the claims and/or specification as follows

IN THE SPECIFICATION.

After the abstract, please delete the existing sequence listing and insert the accompanying substitute sequence listing.

Delete paragraph 174 at page 46 and insert the following replacement paragraph 74:

-----The sequence requirement for the hairpin-ribozyme is any RNA sequence consisting of NNNBN*GUCNNNNNN (where N*G is the cleavage site, where B is any of G, C, or U, and where N is any of G, U, C, or A) (SEQ ID NO:3). Suitable MKP-1 of recognition or target sequences for hairpin ribozymes can be readily determined from the MKP-1 sequence. Certain appropriate sequences include, but are not limited to sequences used as targets for antisense molecules.--